Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) has been given an average recommendation of “Buy” by the twelve brokerages that are currently covering the firm, Marketbeat.com reports. Four analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1 year target price among brokers that have covered the stock in the last year is $49.44.
DCPH has been the subject of a number of research reports. ValuEngine cut shares of Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, August 13th. Leerink Swann reaffirmed a “positive” rating and issued a $29.00 target price (up from $20.00) on shares of Deciphera Pharmaceuticals in a report on Wednesday. Piper Jaffray Companies upped their target price on shares of Deciphera Pharmaceuticals from $50.00 to $55.00 and gave the company an “overweight” rating in a report on Monday, June 3rd. They noted that the move was a valuation call. Deutsche Bank initiated coverage on shares of Deciphera Pharmaceuticals in a report on Thursday, July 18th. They issued a “buy” rating and a $42.00 target price for the company. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $65.00 target price (up from $50.00) on shares of Deciphera Pharmaceuticals in a report on Wednesday.
DCPH traded up $0.70 on Friday, reaching $37.00. The company had a trading volume of 1,813,300 shares, compared to its average volume of 1,282,341. The stock has a 50-day moving average price of $23.38 and a 200-day moving average price of $24.40. Deciphera Pharmaceuticals has a 1 year low of $18.55 and a 1 year high of $42.99. The company has a quick ratio of 7.26, a current ratio of 7.26 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $1.39 billion, a PE ratio of -13.12 and a beta of 2.34.
In other Deciphera Pharmaceuticals news, Director Michael Douglas Taylor sold 22,500 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $40.77, for a total transaction of $917,325.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Thomas Patrick Kelly sold 1,473 shares of the company’s stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $25.06, for a total transaction of $36,913.38. The disclosure for this sale can be found here. Insiders have sold 185,607 shares of company stock valued at $7,536,409 over the last three months. 7.02% of the stock is currently owned by corporate insiders.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Cubist Systematic Strategies LLC lifted its holdings in shares of Deciphera Pharmaceuticals by 55.7% during the second quarter. Cubist Systematic Strategies LLC now owns 13,563 shares of the company’s stock worth $306,000 after buying an additional 4,854 shares in the last quarter. Point72 Asset Management L.P. bought a new position in Deciphera Pharmaceuticals in the second quarter valued at about $4,606,000. Morgan Stanley grew its position in Deciphera Pharmaceuticals by 214.8% in the second quarter. Morgan Stanley now owns 7,864 shares of the company’s stock valued at $177,000 after acquiring an additional 5,366 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Deciphera Pharmaceuticals by 4.2% during the second quarter. Bank of America Corp DE now owns 26,052 shares of the company’s stock worth $588,000 after purchasing an additional 1,062 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of Deciphera Pharmaceuticals by 2.6% in the second quarter. Vanguard Group Inc. now owns 792,654 shares of the company’s stock worth $17,874,000 after acquiring an additional 20,252 shares during the period. Institutional investors own 59.10% of the company’s stock.
Deciphera Pharmaceuticals Company Profile
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.
Featured Article: Momentum Investing
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.